Press Release: Cronos Group Reports 2019 Fourth Quarter and Full-Year Results

Cronos Group Reports 2019 Fourth Quarter and Full-Year Results

Completed Audit Committee Review and Restated Certain 2019 Unaudited Interim Financial Statements

Expanded Canadian distribution to new provinces and product categories across the adult-use market

Established Cronos Fermentation, a critical step in advancing the production of cultured cannabinoids in partnership with Ginkgo Bioworks

Enhanced research and development capabilities at the Peace Naturals Campus

Advanced operational readiness of Cronos Israel with GAP and GMP certifications

TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (\"Cronos Group\" or the \"Company\"), today announces its 2019 fourth quarter and full-year business results.

The Audit Committee of the Cronos Group Board of Directors has completed its review of certain bulk resin purchases and sales of products through the wholesale channel. Following completion of the review, and on the recommendation of the Audit Committee and advice from the Company\'s independent auditor, KPMG LLP, the Board determined that Cronos Group will restate its unaudited interim financial statements for the first, second and third quarters of 2019. Accordingly, the Company reduced revenue for the three months ended March 31, 2019 by C$2.5 million and the three months ended September 30, 2019 by C$5.1 million.

\"We are pleased that the Audit Committee has completed its review, and that Cronos Group is now current with the filing of our financial reports. As we move forward, we are committed to improving our internal controls and financial reporting practices, maintaining the highest standards of transparency and accountability, and enhancing our capabilities and resources across functions to support our strategy,\" said Mike Gorenstein, CEO of Cronos Group.

\"Cronos Group ended 2019 with a strong foundation and balance sheet, and a clear focus on achieving our core strategic initiatives to drive long-term, sustainable growth. Importantly, we expanded our Canadian distribution footprint, broadened our brand portfolio, enhanced our global supply chain capabilities and advanced our breakthrough intellectual property and research and development initiatives. While the world currently faces an unprecedented time of uncertainty related to COVID-19, we believe we are well-positioned to build on these accomplishments as we maintain our investments in brands and products that will resonate with adult consumers and generate sustainable, long-term value for shareholders.\"

Financial Results

(in thousands
of USD) Three months December 31, Change Year ended December 31, Change
2019 2018 $ % 2019 2018 $ %
Net revenue
United
States $ 2,693 $ -- $ 2,693 N/A $ 3,364 $ -- $ 3,364 N/A
Rest of
World 4,615 4,285 330 8% 20,386 12,121 8,265 68%
Consolidated
net revenue 7,308 4,285 3,023 71% 23,750 12,121 11,629 96%

Gross profit
(loss) (20,375) 1,880 (22,255) (1184)% (17,864) 6,213 (24,077) (388)%
Gross margin (279)% 44% -- (323)pp (75)% 51% -- (126)pp

Reported
operating
loss $(63,869) $(8,871) $(54,998) 620% $(121,484) $(21,341) $(100,143) 469%
Adjusted
operating loss
(i) (56,601) (8,871) (47,730) 538% (114,216) (21,341) (92,875) 435%

Other Data
Cash and cash
equivalents 1,199,693 23,927 1,175,766 4914%
Short-term
investments 306,347 -- 306,347 N/A
Capital
expenditures 757 32,676 (31,919) (98)% 38,953 88,586 (49,633) (56)%

(i) See \"Non-GAAP Measures\" for more information, including a reconciliation of adjusted operating loss (ii) Dollar amounts are as of the last day of the period indicated

Fourth Quarter 2019

-- Net revenue of $7.3 million in Q4 2019 increased by $3.0 million from Q4
2018, primarily driven by an increase in the volume of products sold in
the Rest of World segment and the Redwood acquisition, partially offset
by a decrease in the price of products sold in the Rest of World segment.

-- Gross profit (loss) of ($20.4) million in Q4 2019 decreased by $22.3
million from Q4 2018, primarily driven by the inventory write-down of
$24.0 million.

-- The Company incurred an inventory write-down of $24.0 million, made up of
a one-time charge of $1.9 million, related to the repurposing of certain
facilities at the Peace Naturals Campus, and a $22.1 million write-down
on cannabis plants, based on the estimated market value of the specific
strains previously in production, and cannabis oil, primarily driven by
downward pressure in market prices during the year. If we were to adjust
for the effects of the inventory write-down, gross profit in Q4 2019,
would have been $3.6 million, representing a gross margin of 50%. We
anticipate inventory write-downs in the short-term due to pricing
pressures in the marketplace and while the Company executes its
operational repurposing of the Peace Naturals Campus.

-- Reported operating loss of ($63.9) million in Q4 2019 increased by $55.0
million from Q4 2018, primarily driven by the inventory write-down in Q4
2019, one-time charges related to the repurposing of certain facilities
at the Peace Naturals Campus, an increase in general and administrative
expenses in order to support Cronos Group\'s growth strategy, an increase
in sales and marketing in order to create, build and develop brands and
an increase in R&D costs.

-- Adjusted operating loss of ($56.6) million in Q4 2019 increased by $47.8
million from Q4 2018, primarily driven by inventory write-downs in Q4
2019 and an increase in general and administrative expenses in order to
support Cronos Group\'s growth strategy, an increase in sales and
marketing in order to create, build and develop brands and an increase in
R&D costs.

Full-Year 2019

-- Net revenue of $23.8 million in Full-Year 2019 increased by $11.6 million
from Full-Year 2018, primarily driven by an increase in the volume of
sales in the Rest of World Segment due to increases in production,
increases in the volume of wholesale sales and the launch of the
adult-use market in Canada.

-- Gross profit (loss) of ($17.9) million in Full-Year 2019 decreased by
$24.1 million from Full-Year 2018, primarily driven by the inventory
write-down of $29.4 million.

-- The Company incurred an inventory write-down of $29.4 million, made up of
a one-time charge of $1.9 million, related to the repurposing of certain
facilities at the Peace Naturals Campus, and a $27.5 million write-down
on cannabis plants, based on the estimated market value of the specific
strains previously in production, and cannabis oil, primarily driven by
downward pressure in market prices during the year. If we were to adjust
for the effects of the inventory write-downs, gross profit in Full-Year
2019, would have been $11.6 million, representing a gross margin of 49%.

-- Reported operating loss of ($121.5) million in Full-Year 2019 increased
by $100.1 million from Full-Year 2018, primarily driven by inventory
write-downs in Full-Year 2019, an increase in general and administrative
expenses in order to support Cronos Group\'s growth strategy, an increase
in sales and marketing in order to create, build and develop brands and
an increase in R&D costs related to the Company\'s two research
partnerships and one-time charges related to the repurposing of certain
facilities at the Peace Naturals Campus.

-- Adjusted operating loss of ($114.2) million in Full-Year 2019 increased
by $92.9 million from Full-Year 2018, primarily driven by inventory
write-downs in Full-Year 2019, an increase in general and administrative
expenses in order to support Cronos Group\'s growth strategy, an increase
in sales and marketing in order to create, build and develop brands and
an increase in R&D costs related to the Company\'s two research
partnerships.

Business Updates

Brand Portfolio

In December 2019, Cronos Group launched cannabis vaporizer devices for the Canadian adult-use market under the COVE(TM) and Spinach(TM) brands. In conjunction with this launch, the Company created new, tailored 510 thread vaporizer product lines for the COVE(TM) and Spinach(TM) brands, including cartridges that are tamper resistant, made from high-quality stainless-steel components and food grade silicone and have rechargeable draw batteries to prevent overheating. The formulations use premium cannabis extract and come in all-natural terpene-rich flavors. The vaporizer products are currently available at cannabis control authorities in Ontario, British Columbia, Manitoba, New Brunswick, and Nova Scotia, as well as from private-sector retailers in Saskatchewan.

In the fourth quarter, we successfully executed three holiday pop-up shops in Los Angeles and New York City to provide consumers with a curated retail experience of its Lord Jones(TM) products.

(MORE TO FOLLOW) Dow Jones Newswires

March 30, 2020 16:03 ET (20:03 GMT)

Press Release: Cronos Group Reports 2019 Fourth -2-

Cronos Group made the decision to pause distribution of PEACE+(TM) hemp-derived CBD tinctures through Altria Group. Inc.\'s (\"Altria\") sales and distribution network. Cronos Group remains focused on meeting the demands of adult consumers and will continue to evaluate other product formats and categories that we believe may be more suitable for the PEACE+(TM) brand in the evolving environment.

Global Sales and Distribution

In the fourth quarter, Cronos Group began selling cannabis flower and extract products to cannabis control authorities in Alberta, Manitoba, and Quebec. In addition to the new territories, the Company sells dried flower, pre-rolls, cannabis oils and cannabis extracts through its adult-use brands, COVE(TM) and Spinach(TM), to cannabis control authorities in Ontario, British Columbia, Nova Scotia and Prince Edward Island, as well as to private-sector retailers in Saskatchewan.

On October 25, 2019, Cronos Australia announced the closing of an A$20.0 million initial public offering. Cronos Group currently holds approximately 31 percent of the issued capital of Cronos Australia. With the initial public offering complete, Cronos Group is positioned to continue participating in Cronos Australia\'s growth in the medicinal market in the Asia-Pacific region while generating value for the Company\'s shareholders.

In the fourth quarter of 2019, Cronos Group completed its first test export of PEACE NATURALS(TM) branded cannabis oil products to Cronos Australia for distribution to the Australian medical market.

Global Supply Chain

In November 2019, Cronos Group began an operational redesign at the Peace Naturals Campus to better align the business with our strategic priorities. As part of this effort, specific facilities at the Peace Naturals Campus are in the process of being repurposed from cultivation to R&D, with a focus on developing new technologies for value-added product manufacturing, and production of derivative products. This redesign will also increase vault and warehousing capabilities at the facility.

In the fourth quarter of 2019, the Company recorded pre-tax charges of $7.2 million related to the repurposing efforts at the Peace Naturals Campus, with $1.9 million associated with an inventory write-down and $5.3 million of operating expenses, primarily related to impairment costs. The Company does not expect to incur any further significant costs related to the repurposing activities.

The Cronos Israel facility continues to move closer to operational readiness. Construction of Cronos Israel\'s greenhouse and facility was completed in the third quarter of 2019. In December 2019, Cronos Israel successfully achieved GAP certification for propagation and cultivation, as well as GMP certification for the manufacturing and production facilities. Commencement of operations at the Cronos Israel facility will be subject to obtaining the remaining necessary cannabis production licenses under applicable law.

Intellectual Property Initiatives

Ginkgo Bioworks (\"Ginkgo\") has filed certain patent applications pertaining to biosynthesis of cannabinoids to protect intellectual property developed as part of the research progressing under the partnership with Cronos Group. Under the partnership, Cronos Group is the exclusive licensee of the intellectual property covered by the patent applications for the target cannabinoids.

In July 2019, Cronos Group acquired a GMP compliant fermentation and manufacturing facility (\"Cronos Fermentation\") in Winnipeg, Manitoba. The acquisition is expected to provide the fermentation and manufacturing capabilities needed in order to capitalize on the progress underway with Ginkgo by enabling Cronos Group to produce high-quality cannabinoids at scale using fermentation. In November 2019, a team of engineers, scientists, production and quality assurance personnel previously employed by Apotex Fermentation Inc., joined Cronos Group.

Cronos Group commenced work on developing scale-up and downstream processes at Cronos Fermentation, while in parallel Ginkgo develops microorganisms for producing cultured cannabinoids. As Cronos Group develops the processes and parameters, these learnings will be applied for the strains that will be utilized for commercial production of cultured cannabinoids. Commercial production at the facility is subject to completion of the equipment alignment for cannabinoid-based production, the receipt of the appropriate licenses from Health Canada and the achievement of the relevant milestones under the Ginkgo Strategic Partnership.

Update on COVID-19

Despite the significant challenges posed by the outbreak of COVID-19, as a designated essential business, Cronos Group\'s global facilities currently remain operational. During this unprecedented time, the health, safety and well-being of our employees and our consumers remains Cronos Group\'s top priority. The Company has business continuity plans in place to support its employee base while continuing to develop and produce reliable, high-quality products that meet the needs of consumers. As part of this, the Company implemented certain measures such as, among other measures, work-from-home policies for certain employees, enhanced hygiene and sanitation practices, modified schedules and social distancing protocols at the Peace Naturals Campus, Redwood, Cronos Fermentation, OGBC and Cronos Israel facilities. Cronos Group will continue to act in accordance with guidance from local, federal and international health and governmental authorities, and is prepared to make additional operational adjustments as necessary.

The spread and impact from COVID-19 on the global economy continues to rapidly evolve, and the ultimate impact of the COVID-19 outbreak is uncertain and subject to change. Despite Cronos Group\'s business continuity efforts, the Company may see an impact on certain parts of its business and operations such as operational capacity or supply chain delays. The Company continues to closely monitor the rapidly evolving COVID-19 situation, and the impact it may have on the Company, its customers and its supply chain.

Rest of World Results

Cronos Group\'s Rest of World reporting segment includes results of the Company\'s operations for all markets outside of the United States of America. Cronos Group owns and operates license holders, Peace Naturals and OGBC, and currently sells dried flower, pre-rolls and cannabis extracts in the Canadian adult-use and medical markets. The Company established strategic joint ventures in Canada, Israel and Colombia. Cronos Group currently exports cannabis products to countries that permit the import of such products, such as Germany and Australia.

(in thousands
of USD ) Three months December 31, Change Year ended December 31, Change
2019 2018 $ % 2019 2018 $ %
Cannabis
flower $ 2,877 $ 3,228 $ (351) (11)% $ 15,020 $ 9,210 $ 5,810 63%
Cannabis
extracts 1,678 1,028 650 63% 5,338 2,732 2,606 95%
Other 60 29 31 107% 28 179 (151) (84)%
Net revenue 4,615 4,285 330 8% 20,386 12,121 8,265 68%

Gross profit (21,805) 1,880 (23,685) (1,260)% (19,737) 6,213 (25,950) (418)%
Gross margin (472)% 44% -- (516)pp (97)% 51% -- (148)pp

Reported
operating
loss $(59,066) $(8,871) $(50,195) 566% $(106,928) $(21,341) $(85,587) 401%
Adjusted
operating
loss (i) (51,798) (8,871) (42,927) 484% (99,660) (21,341) (78,319) 367%

(i) (See \"Non-GAAP Measures\" for more information, including a reconciliation of adjusted operating loss)

Fourth Quarter 2019

-- Net revenue of $4.6 million in Q4 2019 increased by $0.3 million from Q4
2018, primarily driven by the introduction of vaporizer products and an
increase in the volume of products sold, which were partially offset by a
decrease in the price of products sold.

-- Gross profit (loss) of ($21.8) million in Q4 2019 decreased by $23.7
million from Q4 2018, primarily driven by the inventory write-down of
$24.0 million.

-- The Company incurred an inventory write-down of $24.0 million, made up of
a one-time charge of $1.9 million, related to the repurposing of certain
facilities at the Peace Naturals Campus, and a $22.1 million write-down
on cannabis plants, based on the estimated market value of the specific
strains previously in production, and cannabis oil, primarily driven by
downward pressure in market prices during the year. If we were to adjust
for the effects of the inventory write-down, gross profit in Q4 2019,
would have been $2.2 million, representing a gross margin of 48%. We
anticipate inventory write-downs in the short-term due to pricing
pressures in the marketplace and while the Company executes its
operational repurposing of the Peace Naturals Campus.

-- Reported operating loss of ($59.1) million in Q4 2019 increased by $50.2
million from Q4 2018, primarily driven by the inventory write-down in Q4
2019, one-time charges related to the repurposing of certain facilities
at the Peace Naturals Campus, an increase in general and administrative
expenses in order to support the segment\'s growth, an increase in sales
and marketing in order to create, build and develop brands and an
increase in R&D costs.

-- Adjusted operating loss of ($51.8) million in Q4 2019 increased by $42.9
million from Q4 2018, primarily driven by inventory write-downs in Q4
2019 and an increase in general and administrative expenses in order to

(MORE TO FOLLOW) Dow Jones Newswires

March 30, 2020 16:03 ET (20:03 GMT)

Press Release: Cronos Group Reports 2019 Fourth -3-

support the segment\'s growth, an increase in sales and marketing in order
to create, build and develop brands and an increase in R&D costs.

Full-Year 2019

-- Net revenues of $20.4 million in Full-Year 2019 increased by $8.3 million
from Full-Year 2018, primarily driven by higher volume of wholesale sales
and an increase in the volume of products sold due to increased cannabis
production and the growth of the adult-use market in Canada.

-- Gross profit (loss) of ($19.7) million in Full-Year 2019 decreased by
$26.0 million from Full-Year 2018, primarily driven by the inventory
write-down of $29.4 million.

-- The Company incurred an inventory write-down of $29.4 million, made up of
a one-time charge of $1.9 million, related to the repurposing of certain
facilities at the Peace Naturals Campus, and a $27.5 million write-down
on cannabis plants, based on the estimated market value of the specific
strains previously in production, and cannabis oil, primarily driven by
downward pressure in market prices during the year. If we were to adjust
for the effects of the inventory write-downs, gross profit in Full-Year
2019, would have been $9.7 million, representing a gross margin of 48%.

-- Reported operating loss of ($106.9) million in Full-Year 2019 increased
$85.6 million from Full-Year 2018, primarily driven by inventory
write-downs in Q4 2019, one-time charges related to the repurposing of
certain facilities at the Peace Naturals Campus, an increase in general
and administrative expenses in order to support the segment\'s growth, an
increase in sales and marketing in order to create, build and develop
brands and an increase in R&D costs.

-- Adjusted operating loss of ($99.7) million in Full-Year 2019 increased by
$78.3 million from Full-Year 2018, primarily driven by inventory
write-downs in Q4 2019, an increase in general and administrative
expenses in order to support the segment\'s growth, an increase in sales
and marketing in order to create, build and develop brands and an
increase in R&D costs.

United States Results

As a result of Cronos Group\'s acquisition of Redwood on September 5, 2019, a manufacturer and distributor of hemp-derived CBD infused products in the United States under the brand, Lord Jones(TM), the Company established the United States reporting segment.

(in thousands Three months Year ended December
of USD) December 31 Change 31, Change
2019 2018 $ % 2019 2018 $ %
Net revenue $ 2,693 -- N/A N/A $ 3,364 -- N/A N/A

Gross profit 1,430 -- N/A N/A 1,873 -- N/A N/A
Gross margin 53% -- N/A N/A 56% -- N/A N/A

Reported
operating
loss $(1,797) -- N/A N/A $(2,777) -- N/A N/A

Fourth Quarter 2019

-- Net revenues of $2.7 million in Q4 2019, driven by expanded distribution
of Lord JonesTM branded products through online sales and an increased
retail channel footprint.

-- Gross profit of $1.4 million in Q4 2019, driven by strong sales prices
and brand equity. Gross margin for Q4 2019 was 53%.

-- Operating loss of ($1.8) million in Q4 2019, driven by increased
investments in sales and marketing and general and administrative
expenses as the business focuses on growth prospects and developing new
brands and products.

Full-Year 2019

-- Net revenue of $3.4 million in Full-Year 2019, driven by the Redwood
Acquisition on September 5, 2019.

-- Gross profit of $1.9 million in Full-Year 2019, driven by sales through
e-commerce, retail and hospitality channels within Q4 2019. Gross margin
in Full-Year 2019 was 56%.

-- Operating loss of $2.8 million in Full-Year 2019, driven by the increase
in gross profit and the increased sales and marketing costs incurred in
relation to the preparation for the launch of the PEACE+(TM) U.S
hemp-derived CBD brand, as well as the introduction of several new U.S.
hemp-derived CBD products under the Lord Jones(TM) brand.

Conference Call

The Company will host a conference call and live audio webcast on Monday, March 30, 2020 at 5:30 p.m. EDT to discuss 2019 fourth quarter and full-year results, the Company\'s outlook and other matters. The call will last approximately one hour. An audio replay of the call will be archived on the Company\'s website for replay. Instructions for the conference call are provided below:

-- Live audio webcast:
https://ir.thecronosgroup.com/events-presentations

-- Toll Free from the U.S. and Canada dial-in: (866) 795-2258

-- International dial-in: (409) 937-8902

-- Conference ID: 6999389

About Cronos Group

Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group\'s portfolio includes PEACE NATURALS (TM), a global health and wellness platform, two adult-use brands, COVE(TM) and Spinach(TM), and two hemp-derived CBD brands, Lord Jones(TM) and PEACE+(TM). For more information about Cronos Group and its brands, please visit: www.thecronosgroup.com.

Forward-looking statements

This press release may contain information that may constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively, \"Forward-Looking Statements\"), which are based upon our current internal expectations, estimates, projections, assumptions and beliefs. All information that is not clearly historical in nature may constitute Forward-Looking Statements. In some cases, Forward-Looking Statements can be identified by the use of forward-looking terminology such as \"expect\", \"likely\", \"may\", \"will\", \"should\", \"intend\", \"anticipate\", \"potential\", \"proposed\", \"estimate\" and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions \"may\" or \"will\" happen, or by discussion of strategy. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact.

Forward-Looking Statements include, but are not limited to, statements with respect to:

-- the uncertainties associated with the COVID-19 pandemic, including our
ability to continue operations, the ability of our suppliers and
distribution channels to continue to operate, and the use of our products
by consumers;

-- laws and regulations and any amendments thereto applicable to our
business and the impact thereof including uncertainty regarding the
application of United States (\"U.S.\") state and federal law to U.S. hemp
(including CBD) products and the scope of any regulations by the U.S.
Federal Drug Administration (the \"FDA\"), the U.S. Federal Trade
Commission (the \"FTC\"), the U.S. Patent and Trademark Office and any
state equivalent regulatory agencies over U.S. hemp (including CBD)
products;

-- expectations regarding the regulation of the U.S. hemp industry in the
U.S., including the promulgation of regulations for the U.S. hemp
industry by the U.S. Department of Agriculture (the \"USDA\");

-- the grant, renewal and impact of any license or supplemental license to
conduct activities with cannabis or any amendments thereof;

-- our international activities and joint venture interests, including
required regulatory approvals and licensing, anticipated costs and timing,
and expected impact;

-- the ability to successfully create and launch brands and further create,
launch and scale U.S. hemp-derived consumer products, including through
the Redwood Acquisition (as defined herein) and cannabis products in
jurisdictions where such products are legal and that we currently operate
in;

-- the benefits, viability, safety, efficacy, dosing and social acceptance
of cannabis including CBD and other cannabinoids;

-- the anticipated benefits and impact of the Altria Group Inc.\'s C$2.4
billion (approximately $1.8 billion) investment in us (the \"Altria
Investment\");

-- the potential exercise of the warrant held by Altria Group Inc.,
pre-emptive rights and/or top-up rights in connection with the Altria
Investment, including proceeds to us that may result therefrom;

-- expectations regarding the use of proceeds of equity financings,
including the proceeds from the Altria Investment;

-- the legalization of the use of cannabis for medical or adult-use in
jurisdictions outside of Canada, the related timing and impact thereof
and our intentions to participate in such markets, if and when such use
is legalized;

-- expectations regarding the potential success of, and the costs and
benefits associated with, our joint ventures, strategic alliances and
equity investments, including the strategic partnership with Ginkgo
Bioworks, Inc.;

-- our ability to execute on our strategy and the anticipated benefits of
such strategy;

-- the ongoing impact of the legalization of additional cannabis product
types and forms for adult-use in Canada, including federal, provincial,
territorial and municipal regulations pertaining thereto, the related
timing and impact thereof and our intentions to participate in such
markets;

(MORE TO FOLLOW) Dow Jones Newswires

March 30, 2020 16:03 ET (20:03 GMT)

Press Release: Cronos Group Reports 2019 Fourth -4-

-- the future performance of our business and operations;

-- our competitive advantages and business strategies;

-- the competitive conditions of the industry;

-- the expected growth in the number of customers using our products;

-- our ability or plans to identify, develop, commercialize or expand our
technology and research and development (\"R&D\") initiatives in
cannabinoids, or the success thereof;

-- expectations regarding acquisitions and the anticipated benefits
therefrom, including the Redwood Acquisition and the acquisition of
certain assets from Apotex Fermentation Inc.;

-- expectations regarding revenues, expenses and anticipated cash needs;

-- expectations regarding cash flow, liquidity and sources of funding;

-- expectations regarding capital expenditures;

-- the expansion of our production and manufacturing, the costs and timing
associated therewith and the receipt of applicable production and sale
licenses;

-- the expected growth in our growing, production and supply chain
capacities;

-- expectations regarding the resolution of litigation and other legal
proceedings;

-- expectations with respect to future production costs;

-- expectations with respect to future sales and distribution channels;

-- the expected methods to be used to distribute and sell our products;

-- our future product offerings;

-- the anticipated future gross margins of our operations;

-- accounting standards and estimates;

-- expectations regarding our distribution network; and

-- expectations regarding the costs and benefits associated with our
contracts and agreements with third parties, including under our
third-party supply and manufacturing agreements.

Certain of the Forward-Looking Statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.

The Forward-Looking Statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) management\'s perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xiii) our ability to continue to operate in light of the COVID-19 pandemic and the impact of the pandemic on sales of our products and our distribution channels; and (xiv) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

By their nature, Forward-Looking Statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, the risk that the COVID-19 pandemic may disrupt our operations and those of our suppliers and distribution channels and negatively impact the use of our products; that cost savings and any other synergies from the Altria Investment may not be fully realized or may take longer to realize than expected; disruption from the Altria Investment making it more difficult to maintain relationships with customers, employees or suppliers; future levels of revenues; consumer demand for cannabis and U.S. hemp products; our ability to manage disruptions in credit markets or changes to our credit rating; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); the potential effects of judicial or other proceedings on our business, financial condition, results of operations and cash flows; volatility in and/or degradation of general economic, market, industry or business conditions; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal (including U.S. federal), state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; changes in regulatory requirements in relation to our business and products; and the factors discussed under the heading \"Risk Factors\" in this press release. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements.

Forward-Looking Statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as at and for periods ended on certain dates and to present information about management\'s current expectations and plans relating to the future, and the reader is cautioned that the Forward-Looking Statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the Forward-Looking Statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-Looking Statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such Forward-Looking Statements. The Forward-Looking Statements contained in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.

Use of Non-GAAP Measures

Cronos Group reports its financial results in accordance with accounting principles generally recognized in the United States (\"GAAP\"). However, management use various measures which are not recognized under GAAP such as adjusted operating loss, adjusted operating loss by business segment and adjusted earnings before interest, tax depreciation and amortization (\"Adjusted EBITDA\"). These non-GAAP measures may not be calculated the same as similarly titled measures used by other companies and should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. Management believes these measures provide useful insight into underlying trends and results and will provide a more meaningful comparison of year-over-year results, going forward. Management uses these metrics for planning, forecasting and evaluating business and financial performance, including allocating resources. Reconciliations of each non-GAAP measure to US GAAP recognized measures are provided below.

Cronos Group Inc.

Consolidated Balance Sheets

As of December 31, 2019 and 2018

(MORE TO FOLLOW) Dow Jones Newswires

March 30, 2020 16:03 ET (20:03 GMT)

Press Release: Cronos Group Reports 2019 Fourth -5-

(In thousands of USD)

As of December 31,
2019 2018
Assets
Current assets
Cash and cash equivalents $1,199,693 $ 23,927
Short-term investments 306,347 --
Accounts receivable, net of current
expected credit loss (\"CECL\") of $136 and
$37 as of December 31, 2019 and 2018,
respectively 4,638 3,052
Other receivables 7,232 2,507
Current portion of loans receivable 4,664 230
Prepaids and other assets 9,395 2,842
Inventory 38,043 7,386
Total current assets 1,570,012 39,944
Investments in equity accounted investees 557 2,960
Advances to joint ventures 19,437 4,689
Other investments -- 297
Loan receivable 44,967 --
Property, plant and equipment 161,809 125,905
Right-of-use assets 6,546 125
Intangible assets 72,320 8,237
Goodwill 214,794 1,314
Total assets $2,090,442 $183,471

Liabilities
Current liabilities
Accounts payable and other liabilities $ 35,301 $ 33,239
Current portion of lease obligation 427 30
Derivative liabilities (Note 28) 297,160 --
Total current liabilities 332,888 33,269
Due to non-controlling interests 1,844 1,566
Lease obligation 6,680 87
Total liabilities 341,412 34,922
Commitments and contingencies (Note 21 & 22)
Shareholders\' equity
Share capital (authorized: 2019 and 2018
-- unlimited; issued: 2019 --
348,817,472; 2018 -- 178,720,022) 561,165 175,001
Additional paid-in capital 23,234 11,263
Retained earnings (accumulated deficit) 1,137,646 (27,945
Accumulated other comprehensive income
(loss) 27,838 (9,870
Total equity attributable to
shareholders of Cronos Group 1,749,883 148,449
Non-controlling interests (853) 100
Total shareholders\' equity 1,749,030 148,549
Total liabilities and shareholders\' equity $2,090,442 $183,471

See notes to consolidated financial statements.

Cronos Group Inc.

Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

For the years ended December 31, 2019, 2018, and 2017

(In thousands of USD, except share and per share amounts)

Year ended December 31,
2019 2018 2017
Net revenue, before
excise taxes $ 25,639 $ 13,234 $ 3,147
Excise taxes (1,889) (1,113) --
Net revenue 23,750 12,121 3,147
Cost of sales 12,174 5,908 1,573
Inventory
write-down 29,440 -- --
Gross profit (loss) (17,864) 6,213 1,574
Operating expenses
Sales and
marketing 23,045 3,173 443
Research and
development 12,155 1,814 --
General and
administrative 49,372 13,447 4,904
Share-based
payments 11,619 8,151 1,931
Depreciation and
amortization 2,101 969 417
Repurposing
charges 5,328 -- --
Total operating
expenses 103,620 27,554 7,695
Operating loss (121,484) (21,341) (6,121)
Other income
(expense)
Interest income
(expense) 27,982 83 (97)
Financing and
transaction
costs (32,208) -- --
Gain on
revaluation of
derivative
liabilities (Note
28) 1,276,819 -- --
Gain on
revaluation of
financial
liabilities 197 -- --
Gain on disposal
of Whistler 15,530 -- --
Gain on other
investments 747 164 3,746
Share of income
(loss) from
investments in
equity accounted
investees (2,009) (723) 127
Total other
income
(expense) 1,287,058 (476) 3,776
Income (loss) before
income taxes 1,165,574 (21,817) (2,345)
Income tax recovery -- -- (862)
Net income (loss) $ 1,165,574 $ (21,817) $ (1,483)
Net income (loss)
attributable to:
Cronos Group $ 1,166,506 $ (21,636) $ (1,483)
Non-controlling
interests (932) (181) 0
$ 1,165,574 $ (21,817) $ (1,483)
Other comprehensive
income (loss)
Foreign exchange
gain (loss) on
translation $ 37,687 $ (12,337) $ 2,456
Gain on
revaluation and
disposal of
other
investments, net
of tax -- 3 415
Unrealized gains
reclassified to
net income -- -- (12)
Total other
comprehensive
income (loss) 37,687 (12,334) 2,859
Comprehensive income
(loss) $ 1,203,261 $ (34,151) $ 1,376
Comprehensive income
(loss) attributable
to:
Cronos Group $ 1,204,214 $ (33,964) $ 1,376
Non-controlling
interests (953) (187) --
$ 1,203,261 $ (34,151) $ 1,376
Net income (loss)
per share
Basic $ 3.76 $ (0.13) $ (0.01)
Diluted 3.33 (0.13) (0.01)
Weighted average
number of
outstanding shares
Basic 310,067,179 172,269,170 134,803,542
Diluted 342,811,992 172,269,170 176,789,161

See notes to consolidated financial statements.

Cronos Group Inc.

Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

For the quarters ended December 31, 2019 and 2018

(In thousands of USD, except share and per share amounts)

Three months ended December 31,
2019 2018
Net revenue, before excise
taxes $ 7,915 5,398
Excise taxes (607) (1,113)
Net revenue 7,308 4,285
Cost of sales 3,667 2,405
Inventory write-down 24,016 --
Gross profit (20,375) 1,880
Operating expenses
Sales and marketing 13,324 1,970
Research and development 6,079 1,814
General and
administrative 14,314 4,544
Share-based payments 3,670 2,183
Depreciation and
amortization 779 240
Repurposing costs 5,328 --
Total operating
expenses 43,494 10,751
Operating loss (63,869) (8,871)
Other income (expense)
Interest income
(expense) 7,514 177
Financing and
transaction cost (524) --
Gain (loss) on
revaluation of
derivative liabilities
(Note 11) 118,811 --
Gain on other
investments 2 (225)
Gain on disposal of
Whistler Medical
Marijuana Company 32 (15)
Share of income (loss)
from investments in
equity accounted
investees (505) (758)
Gain (loss) on
revaluation of financial
liabilities 50 --
Total other income (expense) 125,380 (821)
Income (loss) before
income taxes 61,511 (9,692)
Income tax recovery 58 --
Net income (loss) 61,569 (9,692)
Net income (loss)
attributable to:
Cronos Group $ 62,005 (9,558)
Non-controlling interests (436) (134)
$ 61,569 (9,692)
Other comprehensive income
(loss)
Foreign exchange gain
(loss) on translation $ 28,264 (8,511)
Gain on revaluation and
disposal of other
investments, net of

(MORE TO FOLLOW) Dow Jones Newswires

March 30, 2020 16:03 ET (20:03 GMT)